Retatrutide's 22.6% Weight Loss Masked by Unresolved CV Benefit Gap

References

1. 1.Chen, E. (2026, July 23). New data on Eli Lilly's 'triple-G' drug leave open questions on heart benefit. STAT News. https://www.statnews.com/2026/07/23/new-data-on-eli-lilly-triple-g-drug-retatrutide-leave-open-questions-on-heart-benefit/
2. 2.Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
3. 3.Eli Lilly and Company. (2024). SURMOUNT-MMO: A study of tirzepatide on the reduction of morbidity and mortality in adults with obesity [Clinical trial registration NCT05556512]. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05556512
4. 4.Sattar, N., McGuire, D. K., & Pavo, I. (2023). Cardiovascular outcome trials in obesity: What have we learned and what do we need? The Lancet Diabetes & Endocrinology, 11(9), 624–635. https://doi.org/10.1016/S2213-8587(23)00177-3
5. 5.Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
6. 6.Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. https://doi.org/10.1186/s12933-022-01604-7
7. 7.Pharmaceutical Benefits Advisory Committee (PBAC). (2024). PBAC guidelines: Requirements for clinical evidence in submissions for obesity pharmacotherapies. Australian Government Department of Health and Aged Care. https://www.pbs.gov.au/info/industry/listing/elements/pbac-guidelines
8. 8.Ryan, D. H., & Lingvay, I. (2024). Cardiovascular outcomes as the new standard for obesity drug approval: Implications for clinical practice and drug development. Obesity Reviews, 25(4), e13700. https://doi.org/10.1111/obr.13700